ÂÜÀòÂÒÂ×

Mani Mohindru, PhD, is an accomplished executive with extensive experience in the biotechnology and pharmaceutical sectors. Currently serving as the Chief Executive Officer of Novasenta since April 2021, Mani also holds board positions at CytomX Therapeutics and Cardiff Oncology. In addition, Mani is an Executive Advisory Board Member at Northwestern University's Chemistry of Life Processes Institute. Previous leadership roles include CEO of CereXis, CFO and Chief Strategy Officer at Cara Therapeutics, and Chief Strategy Officer at Curis, Inc. Mani co-founded Immtox LLC and worked as a Senior Research Analyst at ThinkEquity LLC. Academic credentials include a PhD in Neurosciences from Northwestern University, a B.Sc (Hons) in Human Biology, and a Masters in Biotechnology from the All India Institute of Medical Sciences.